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Abstract
Objective: Balloon-expandable stent valves require flow reduction during implantation (rapid pacing). The present study was designed to
compare a self-expanding stent valve with annular fixation versus a balloon-expandable stent valve. Methods: Implantation of a new self-
expanding stent valve with annular fixation (SymetisW, Lausanne, Switzerland) was assessed versus balloon-expandable stent valve, in a modified
Dynatek DaltaW pulse duplicator (sealed port access to the ventricle for transapical route simulation), interfaced with a computer for digital
readout, carrying a 25 mm porcine aortic valve. The cardiovascular simulator was programmed to mimic an elderly woman with aortic stenosis:
120/85 mmHg aortic pressure, 60 strokes/min (66.5 ml), 35% systole (2.8 l/min). Results: A total of 450 cardiac cycles was analysed. Stepwise
expansion of the self-expanding stent valve with annular fixation (balloon-expandable stent valve) resulted in systolic ventricular increase from
120 to 121 mmHg (126 to 830  76 mmHg)*, and left ventricular outflow obstruction with mean transvalvular gradient of 11  1.5 mmHg
(366  202 mmHg)*, systolic aortic pressure dropped distal to the valve from 121 to 64.5  2 mmHg (123 to 55  30 mmHg) N.S., and output
collapsed to 1.9  0.06 l/min (0.71  0.37 l/min* (before complete obstruction)). No valve migration occurred in either group. (* = p < 0.05).
Conclusions: Implantation of this new self-expanding stent valve with annular fixation has little impact on haemodynamics and has the potential
for working heart implantation in vivo. Flow reduction (rapid pacing) is not necessary.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Transluminal artificial heart valve implantation was first
reported, in an in vivo experimental study, by Andersen in
1992 [1]. Cribier et al. described the first human clinical
implantation in 2002 [2].
Since 2006, literature on percutaneous heart valve
therapies burst out, with more than 300 patients cohort
published at that date (Pubmed). In 2008, according to
European societies’ position statement on transcatheter
aortic procedure [3], 1200 high-risk patients with severe
symptomatic aortic stenosis have been treated using
transcatheter aortic valve implantation.
After first feasibility studies (I-REVIVE, US-REVIVAL and
RECAST), several clinical trials are on the way (REVIVE,
REVIVAL II), and even now, prospective randomised trials are§ Presented at the 22nd Annual Meeting of the European Association for
Cardio-thoracic Surgery, Lisbon, Portugal, September 14—17, 2008.
* Corresponding author. Address: Service de Chirurgie Cardio-Vasculaire et
Transplantation C, Hoˆpital Cardiothoracique Louis Pradel, 28 Avenue du Doyen
Le´pine, Lyon-Bron, 69677, France. Tel.: +33 4 72 35 75 46;
fax: +33 4 72 35 73 83.
E-mail address: mathieu.vergnat@chu-lyon.fr (M. Vergnat).
1010-7940/$ — see front matter # 2009 European Association for Cardio-Thoracic S
doi:10.1016/j.ejcts.2009.01.052on the way (PARTNER). Moreover, numerous transcatheter
heart valve devices are in development.
However, percutaneous aortic valve replacement has
been noteworthy rapidly brought to clinics and lack of
experimental studies is significant, for this potentially life
threatening procedure. At the time of writing, a Pubmed
search with the terms ‘percutaneous heart valve’ and ‘in
vitro restriction’, brings up only two studies [4,5]. Consider-
ing animal studies, the same investigation results in 9 studies
for aortic valve before 2002 (date of Cribier first in man
publication), 14 studies for aortic valve before 2006
(beginning of large cohort studies).
Haemodynamics during percutaneous aortic valve repla-
cement is a major concern, especially regarding left
ventricular overpressure, as procedures are performed on
low ejection fraction hearts (part of the high-risk patients).
Rapid pacing for these devices (balloon-expandable stent
valve) is necessary. While this topic has been briefly studied
for percutaneous aortic valvuloplasty [6—10], only one study
get onto haemodynamics during percutaneous heart valve
therapies [11].
The purpose of this studywas to observe in vitro the impact
that the new percutaneous heart valve replacementmay haveurgery. Published by Elsevier B.V. All rights reserved.
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conditions, an in vitro model using an electrohydraulic pulse
duplicator was used. Two main type of stent were used:
balloon-expandable stent valve (Balloon SV) and self-expand-
ing stent valve (self SV). The new SymetisW self-expanding
stent valve with annular fixation was assessed.
2. Materials and methods
The design of the in vitro circulatory system (Fig. 1) was
based on Dynatek Dalta MP3W (Dynatek DaltaW, Galena, MO,
USA) hydrodynamic pulse duplicator.
This cardiovascular simulator consists of a double-valved
left ventriclechamberconnected toa compliantvascular loop.
Left ventricle is connectedwithapiston, computer controlled,
volumetric pump,withadjustable strokevolumeandduration.
Pulsatile flow is generated (maximum 10 l/min). Each stroke
ejects 30—100 mlof saline solution into the circuit. The system
possesses an open reservoir and compliant tubing to simulate
venous and arterial system, respectively. In addition, periph-
eral vascular resistance/compliance and systolic/diastolic
aortic pressure were adjusted by using loop clamps.Fig. 1. The cardiovascular simulator. A double-valved (mitral (MV) and aortic
valves (AoV)) left ventricle (V) is connected with a piston volumetric pump
(PP). A compliant vascular loop and a systemic reservoir (R) simulate arterial
and venous systems. Vascular resistance is adjusted by clamps. Piezoelectric (a
and b) and ultrasound (c) sensors allow for continuous monitoring and com-
puter control adjustment. Sealed port-access to the circulatory system has
been created to simulate transapical (1) and transfemoral (2) routes.Versatility of the system allows for a large panel of
physiological/pathological conditions, with control of dP/dt
ratio.
An ultrasonic probe (TransonicW Laboratory Tubing
Flowmeter T110, Transonic Systems Inc., Ithaca, NY, USA)
was placed on the outflow tubing to assess cardiac output.
Ventricular and aortic pressure (piezoelectric sensors), flow
rates (ultrasound sensor) are monitored continuously (sam-
pling rate: 2000 Hz).
A mechanical valve has been placed in the mitral position.
In order to mimic anatomic environment, a stentless
bioprosthesis was attached in aortic position. A 25 mm inner
diameter stentless porcine aortic bioprosthesis was used. The
valve was sutured in a 27 mm inner diameter rigid silicon
tube, applying a reimplantation procedure. Soft moss
material was fixed under the valve, mimicking annulus, to
increase sealing in the non-compliant silicon tube. The tube
was then connected to the circulation. Stent valves were
implanted in that environment.
Sealed port access to the ventricle has been created for
transapical route implantation (33F inside diameter).
Another peripheral access has been developed for transfe-
moral access implantation.
Visualisation of the simulated aortic root was possible
through the transparent silicon tube, or by an endoscope
inserted through the transarterial access.
Saline (0.9%) was used as fluid.
In this simulated circulation, blood pressure, heart rate
and cardiac output can be chosen to mimic physiological/
pathological conditions. The testing conditions were set to
mimic low cardiac output in an elderly woman at rest (under
anaesthesia). The following haemodynamic conditions were
produced: pressure, heart and flow rates, stroke volume and
systolic duration respectively 120 mmHg systolic, 85 mmHg
diastolic, 60 beats/min, 2.8 l/min, 66.5 ml, 35% of cycle.
Stent valves were used: a self-expanding stent valve and a
balloon-expandable stent valve.
The new SymetisW aortic stent valve (Symetis, Lausanne,
Switzerland) was used for self-expanding stent valve
implantation. This device consists of an aortic stentless
porcine valve that is mounted and sutured in a self-expanding
nitinol alloy stent (Fig. 2), with a Dacron interface. The
double-crown design of the device is specially adapted to
anchor on the aortic annulus and allows self-positioning.
Inner diameter of the stent valve used was 25 mm. The
device was inserted by means of a self-constructed rigid
catheter-based (32F outside diameter) delivery technique
through the sealed ventricular port access.
A 23 mm percutaneous valvuloplasty catheter (Cristal
Balloon CVB23  45/110, Balt, Montmorency, France) was
used to simulate balloon-expandable stent valve implantation.
Stepwise of implantation of valved stents was simulated.
The positioning of the valved stents into the valve chamber
was enabled by means of direct view through the transparent
silicone tube. All data (arterial and ventricular pressure,
heart rate and cardiac output) were digitised and con-
tinuously recorded with the Dynatek Dalta software. Seven
steps were studied for the balloon-expandable stent valve
and eight for the self-expanding stent valve, 30 cycles
analysed on each step (16 only for extreme positions with
800 mmHg ventricular pressure). A total of 450 cycles
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Fig. 2. The new SymetisW aortic stent valve (Symetis, Lausanne, Switzerland).
Table 1
Systolic ventricular pressure (SVP), mean gradient, systolic arterial pressure
(SAP), mean arterial pressure (MAP), diastolic arterial pressure (DAP), during
stepwise implantation.
SVP Mean gradient SAP MAP DAP
Self SV
a 119.8  0.3 0.3  0.1 121.1  0.3 108.1  0.4 93.3  0.4
b 121.6  0.6 2.1  0.1 122.9  0.6 110.1  0.7 95.3  0.7
c 118.6  0.2 2.3  0.1 119.7  0.2 106.6  0.2 91.1  0.3
d 79.4  0.3 5.8  0.1 79.4  0.3 60.5  0.3 38.4  0.4
e 67.1  3.6 11  1.4 64.4  2.3 43  2.8 19.1  3
f 66.7  0.3 10.1  0.3 65.7  0.3 44.4  0.4 20.4  0.4
g 83.2  0.6 7.5  0.2 82.8  0.6 63.9  0.7 41.7  0.8
h 104  0.4 3.3  0.1 104.5  0.4 88.9  0.4 70.7  0.5
Balloon SV
a 126.2  0.2 2.9  0.1 123.3  0.2 110.2  0.2 95.8  0.3
b 120.4  0.7 3  0.1 117.4  0.6 103.4  0.5 88.1  0.6
c 122.5  0.9 7.1  0.4 117.5  0.9 103.3  1 88.1  1.1
d 136.1  0.9 15.5  0.7 120.4  0.6 107.2  0.6 92.2  0.8
e 401.4  44.2 180  26.4 106.7  2.9 94  3.1 80.6  3
f 829.7  76.1 365.9  202.3 55.8  30.7 44.1  24.7 34.3  21.3
g 121.6  0.2 1  0.1 121.3  0.2 107.8  0.2 92.5  0.3
Data are expressed in mmHg. Delivery steps are highlighted.recorded at 2000 Hz sampling rate for each variable (aortic
and ventricular pressure, outflow) resulted in 2,700,000
values to process.
Stepwise implantation of self-expanding stent valve
consisted of:
a. baseline
b. release-catheter through the valve




g. self-expanding stent valve without delivery catheter
h. self-expanding stent valve after balloon dilatation (wall
application of the device).
Stepwise implantation of balloon-expandable stent valve
consisted of:
a. baseline
b. balloon valvuloplasty catheter through the valve
c. balloon filled with 5 cc saline with 0.5 bar pressure
d. balloon filled with 10 cc saline with 1 bar pressure
e. balloon filled with 15 cc saline with 3 bar pressure
f. balloon filled with 17.5 cc saline with 4 bar pressure
g. balloon-expandable stent valve.
Delivery is step e on self-expanding stent valve implanta-
tionand step f inballoon-expandable stent valve implantation.
Complete obstruction of the simulator was not performed
(23 mm balloon in a 25 mm native valve), to prevent
explosion of the system at mechanical boundaries.Data analysed were systolic, diastolic and mean arterial
pressure (SAP, DAP, MAP), systolic ventricular pressure (SVP),
mean transvalvular gradient, mean outflow and regurgitation
fraction (RF). Results were expressed as mean  standard
deviation.
Mann—Whitney test was used to compare measurements
between the two groups, and a p value less than 0.05 was
considered significant.
3. Results
During self-expanding stent valve implantation, systolic
ventricular pressure rose from 120 mmHg to a maximum of
121  0.6 mmHg, as delivery catheter was inserted (step b)
(Table 1). Maximum left ventricular outflow obstruction
assessed by a mean transvalvular gradient of 11  1.4 mmHg
was observed during delivery (step e) (Fig. 3). Systolic
arterial pressure decreased to a minimum of 64  2 mmHg
during delivery (step e), while cardiac output nadir value
was, after delivery catheter pull back, of 1.9  0.07 l/min
(Table 2).
For balloon-expandable stent valve implantation,
all boundary values were observed during maximum
balloon inflation (step f). Differences with SESV were
statistically ( p < 0.05) significant (marked as *), for all
boundary values, except for SAP and MAP (Table 3 and
Fig. 4).
Stepwise expansion of the balloon-expandable stent
valve resulted in a significatively higher systolic ventricular
pressure increase from 126 to 830  76 mmHg* (Table 1).
Peak left ventricular outflow obstruction with mean
transvalvular gradient of 366  202 mmHg* was observed
with balloon inflated with 17.5 cc (Fig. 5). Systolic aortic
pressure dropped distal to the valve from 123 to
56  31 mmHg (non-significant (N.S.)), and output collapsed
to 0.71  0.37 l/min (before complete obstruction)*
(Table 2).
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Fig. 4. Systolic ventricular pressure (SVP), mean gradient, systolic arterial
pressure (SAP), mean arterial pressure (MAP), at boundaries conditions. Data
are expressed in mmHg and l/min. *p < 0.05. NS: not significant.
Table 2
Mean outflow (l/min) and regurgitating fraction (RF) (%) during stepwise
implantation. Delivery steps are highlighted.
Mean output (l\min) RF%
Self SV
a 2.70  0.08 11.9  1.5
b 3.57  0.09 12.1  1.4
c 3.53  0.12 13.8  1.1
d 2.66  0.20 37.9  1.4
e 2.32  0.14 46.2  3.0
f 2.39  0.09 45.0  1.0
g 1.88  0.07 39.0  0.9
h 2.24  0.05 25.9  0.8
Balloon SV
a 2.76  0.05 12.3  1.0
b 2.65  0.11 16.6  1.5
c 2.50  0.08 18.6  1.3
d 2.58  0.05 15.0  1.5
e 2.32  0.08 17.6  1.9
f 0.71  0.37 48.1  25.7
g 2.85  0.12 13.8  1.0
Fig. 5. Systolic ventricular pressure (SVP) (mmHg) and mean aortic gradient
(mmHg) during Balloon SV implantation. Delivery is step f.
Fig. 3. Systolic ventricular pressure (SVP) (mmHg) and mean aortic gradient
(mmHg) during self SV implantation. Delivery is step e.4. Discussion
First in vitro model for aortic stent valve implantation is
proposed. Efficient in vitro stent valve implantation assess-
ment, with detailed haemodynamics, can be realised.
Percutaneous stent valve implantation has increasingly
become a therapy for aortic stenosis. Haemodynamics during
implantation is a critical step, as referred to its consequences
(effects on recipient heart and device positioning).
Some in vitro percutaneous valve studies [12—16] have
been reported but none of these are relative to haemody-
namic conditions during implantation. To our knowledge, this
is the first in vitro model of working heart transcatheter
aortic valve implantation. The aim of this study was to
continuously assess flow and pressure throughout implanta-Table 3
Systolic ventricular pressure (SVP), mean gradient, systolic arterial pressure (SAP),
SVP Mean gradient
Self SV 121.6  0.6 (b) 11  1.4 (e)
Balloon SV 829.7  76.1* (f) 365.9  202.3* (f)
Data are expressed in mmHg and l/min. Letter indicates the step during delivery (
delivery; g, after delivery; balloon-expandable stent valve: f, balloon filled with 17tion of the two most used kind of stent valves. The new
Symetis self-expanding stent valve was assessed.
Some studies about haemodynamics during valvuloplasty
have been reported in the late eighties [6—10]. Nevertheless,
clinical limited application stopped this research fields early.
In vitro evaluation of aortic valvuloplasty [7] revealed that
magnitude of transvalvular gradient during obstruction is
flow dependant, thus protecting heart failure patients.
However, for critical narrowing, minute alterations of orifice
size may induce significant changes of this gradient. Sua´rez
De Lezo [8] showed that during occlusion of left ventricle,
hypertension is transmitted to all cardiac chambers. Adap-
tion is generated by regurgitation through atrioventricular
valves and foramen ovale, acting as escape orifices relieving
intracavitary pressures.
Among valved stents, balloon-expandable stent valve
devices have been historically developed first and brought to
clinic (Cribier—EdwardsW aortic prosthesis (Edwards Life-
sciences, CA, USA)).
Our results showed clinically significative modifications of
haemodynamic status during implantation simulation of
balloon-expandable stent valve. As a result of outflow
obstruction, systolic pressure rose in the unvented ventricle,mean arterial pressure (MAP), at boundaries conditions.
SAP MAP Mean output
64.4  2.3 (e) 43  2.8 (e) 1.88  0.07 (g)
55.8  30.7 (f) 44.1  24.7 (f) 0.71  0.37* (f)
self-expanding stent valve: b, release-catheter through the valve; e, during
.5 cc saline with 4 bar pressure). *p < 0.05. NS: not significant.
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balloon.
Two consequences of this obstruction are concerning.
First, acute overpressure occurs on a chronically high
pressure exposed ventricle. This issue is real, as percuta-
neous heart valve procedure has been designed to treat high-
risk patients. However, Bittl et al. showed in an in vivo human
study, that peak left ventricular systolic pressure during
valvuloplasty correlates closely with left ventricular function
[6]. Secondly, transvalvular gradient reflects migration
forces applied to the delivery system, which may result in
device malpositioning.
This study confirms the non-alternative need for flow
reduction (rapid pacing) in balloon-expandable stent valve
implantation. Nevertheless, evolution of systolic ventricular
overpressure (and its ventricular and device positioning
consequences) during percutaneous aortic valve implanta-
tion under rapid pacing has never been studied.
Various methods have been described to transiently
reduce intracardiac flow during interventional procedures.
Ventricular fibrillation has been induced to facilitate
endovascular stent implantation [18]. Rapid pacing was
described by Daehnert et al. [19] in paediatric valvuloplasty
and used by Cribier et al. [20,21] during valvuloplasty and
valve implantation. A concern with rapid pacing is the
potential for provoking ventricular arrhythmias; of particular
concern in patients with aortic stenosis hypertrophic hearts.
Webb et al. described an occurrence of 3% in 40 consecutive
patients, but concealed more frequent arrhythmia in other
settings than those used in the study [17]. The author
concludes with cautious advice and prudent attitude, by
limiting frequency and duration of pacing so far as possible.
However, although non-physiological approach, rapid pacing
is more and more used in transcatheter valvular procedure
field, and is now considered as safe procedure in experienced
hands.
Other options could be considered to decrease ventricular
outflow (and over-pressure) in percutaneous heart valve
procedures. Reducing inflow, by balloon occlusion of proximal
vasculature, results in lower output, as described by Marty
et al. [22]. Other methods proposed are cardiopulmonary
assistance, adenosine-induced ventricular standstill.
Antegrade delivery of the new Symetis self-expanding
stent valve showed significatively reduced impact on
haemodynamics (as opposed to balloon-expandable stent
valves) and thus, potential for working heart implantation in
vivo. Throughout delivery, output was maintained, with a
nadir SAP value of 64  2.3 mmHg.
The first and only available self-expanding stent valve for
clinical use is the CorevalveW revalving system [23]. This
device, initially implanted under cardio-pulmonary bypass,
required, in initial experience, rapid pacing, to improve
device positioning. Though not reported in literature,
centres using this device now report implantation without
rapid pacing.
This study showed the Symetis stent valve can be
implanted by antegrade route, on working heart. No flow
reduction (rapid pacing) is required (as opposed to balloon-
expandable stent valves.
These advantages have two consequences as opposed to
balloon-expandable stent valve. No clinically relevanthaemodynamic modifications and output preserve. Left
ventricle is not exposed to acute overpressure. This more
physiologic approach could be an asset in treating high-risk
patients.
Another effect of this is a secure positioning. As gradient is
no more than 11  1.4 mmHg, migration forces applied on
the delivery catheter are lower than the restraining forces of
ventricular introducer valve on the delivery catheter. In
predelivery position (step to exactly position the device),
only uncovered upper crown is deployed and exposed to the
flow. This low profile does not obstruct blood flow. In
addition, the design of the stent allows for secured
positioning of the device in the aortic annulus. Auto-
positioning of the stent after delivery, under diastolic
pressure, is a consequence of the double-crown system.
Haemodynamic status during valve implantation is one of
the several complex aspects of multifaceted transcatheter
aortic valve implantation procedure. It could be, as for
access route, one of the factors taken into account for the
decision of which delivery system to use for each patient.
Numerous other factors will be considered in future
assessment of transcatheter valvular device, such as
durability of valve and stent of each device.
5. Limitations of the study
Themain limitation of the study is the use of a volumetric,
non-adaptive pump. A barometric pulse duplicator would
have provided less pathologic flow and pressure patterns.
However, assessment of self-expanding stent valve implanta-
tion procedure was more close to reality than balloon-
expandable stent valves, and proved the absence of
ventricular over pressure. This study validated the haemo-
dynamic consistency of the new device. This proof of concept
is required, but not sufficient, for stepping to in vivo
experiment. Moreover, this left ventricle overpressure led us
to create a new concept for ventricular venting, before in
vivo testing.
Post implantation haemodynamic assessment was not
optimal. The rigid silicone tube holding aortic native valve
was not molded to receive profiled stent valve. Even with the
help of sealing moss, post implant leaks were important,
misleading haemodynamic assessment. However, design of
the study was not intended to assess haemodynamics after
but during implantation.
Saline temperature was ambient. Nitinol requires heating
for complete unfolding. This led to non-optimal adaption of
the device to the aortic mock-up, increasing parastental
leakage.
Another limitation is the use of normal native valve.
However, in vitro studies should be undertaken prior to
expensive in vivo studies; they should serve as a filter to test
and eliminate early designs and techniques. The superior in
vivo approach would also be limited by the lack of an
experimental animal model with calcified aortic stenosis.
Recognition of the multiple limitations of present day models
does not invalidate attempts at dissecting the multiple
problems of percutaneous aortic valve replacement. More-
over, some authors consider PAVR for wider application than
aortic stenosis patients [24].
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Appendix A. Conference discussion
Dr G. Wimmer-Greinecker (Bad Bevensen, Germany): It is absolutely true,
that the crucial parts of those procedures are the placement and the
positioning of this valve. So let me ask you three questions.
From your manuscript I understand that your setup is a pulsatile one. So
what I don’t really understand is your comment on the migration forces. Why
do you think this is only depending on the transvalvular gradient? I would see
this in a nonpulsatile setting, but in a pulsatile setting I think there are more
things that contribute to those forces.
The second question is how do those data reflect the two on the market
available valves? As we have seen several times during this meeting and also
today the CoreValve is still implanted in most cases with rapid pacing. So what
is the difference with your valve? Is it the valve itself or is it the delivery
system?
And the last question. Have you also tried this experiment under different
hemodynamic conditions? I mean, it is not only that we have different
individuals but even during a procedure, due to the application of fluids and
vasopressors, we do have different hemodynamic conditions. They might vary,
and so the situation is not as stable as you have shown in your experiments.
Dr Vergnat: My understanding of the migration forces is that during
balloon-expandable stent-valve implantation you have high gradients, with
high pressure in the ventricle and low pressure in the aorta. That can move up
your delivery balloon catheter towards the aorta. That is why, for me, it is very
important. And during self-expanding stent-valve implantation, the flow is
going around the delivery device. So the flow is maintained; there is no
gradient. Thus you can place your device exactly where you want. The flow is
going on, you have the time, and that is it.
Dr Wimmer-Greinecker: But in a pulsatile system, the flow is changing.
Dr Vergnat: In calcified aortic stenosis you mean?
Dr Wimmer-Greinecker: No, I mean the difference between systolic and
diastolic pressures.
Dr Vergnat: Yes, but as I showed you on the self-expanding stent-valve
assessment, there was no traction on the catheter. I can just leave the catheter
inside, and the flow is going on, with the systolic pressure, and diastolic
pressure, and it is not moving. If you have a balloon inside, the balloon is going
into the aorta. So that is why for memigration forces are very linked during the
implantation to the ventriculo-aortic gradients.
About your second question, the difference between this device and the
CoreValve device, it is difficult to speak about that, as I never used the
CoreValve stent valve, I never had it in the hands and never went into an
implantation. But what we have on that device design (SymetisW self
expanding StentValve) that you don’t have anymodification of the gradient. So
you can position it very precisely. And then you have this double-crown design
that can allow auto-positioning of the device. When you just release it, the
device is self-positioning into the aortic annulus with this double-crown design.
That could be better. And you can answer me that on calcified leaflets, it would
be different. But maybe the future is near [aortic regurgitation indications]
Your last question was, it was not stable during the implantation?
Dr Wimmer-Greinecker: No. You only did this experiment under one kind
of hemodynamic condition. So have you tried this at different cardiac outputs?
M. Vergnat et al. / European Journal of Cardio-thoracic Surgery 35 (2009) 970—976976Dr Vergnat: No, we didn’t do that. It could be very interesting. At that
outflow you don’t havemigration forces. I don’t think you will find anymigration
forces in higher output. The second thing is, I don’t know if you saw the pressure
figures in theventriclewhen itwasobstructedwith theballoon-expandable stent
valve. It was 800 mmHg, and I didn’t want my system to explode.Dr P. Kappetein (Rotterdam, The Netherlands): One remark. When you
implant the CoreValve device, you don’t need rapid pacing. When we started
we used extracorporeal circulation, then we found out that rapid pacing was
sufficient, and then we discovered that actually you don’t need any rapid
pacing during the implantation.
